The Toronto-based pharmaceutical royalties company said its board “demanded and received the immediate resignation” of CEO Behzad Khosrowshahi, due to an ongoing investigation into alleged irregularities in expense reimbursement requests and consulting fees. Its shares fell over 26per cent on the Toronto Stock Exchange on Monday afternoon. (The Logic)
Talking point: DRI’s chief financial officer Chris Anastasopoulos was also suspended with pay pending the outcome of the investigation by independent legal counsel and forensic accountants, which is being overseen by an audit committee of independent trustees. Although the probe isn’t complete, the company estimated that about $7.5 million in restitution may be needed to account for the consulting fees and other expenses. Board chair Gary Collins, a former British Columbia finance minister, was named interim CEO of DRI Healthcare Trust. Board member Ali Hedayat was named interim CEO of DRI Healthcare, while DRI’s vice-president of finance Sandy Kwan will be interim CFO of both firms.